• Fenling Fan, Yifan Zou, Youson Wang, Peng Zhang, Yuping Zhang, Qiang Song, Anthony M Dart, and Yuliang Zou.
• Department of Cardiovascular Medicine, the First Hospital of Xi'an Jiaotong University, Xi'an, China.
• Int. J. Clin. Pract. 2021 Oct 1; 75 (10): e14619.

PurposeIn ambulant patients with lower limb DVT managed with Warfarin, there is a need for initial treatment and short time "bridging" with a rapidly acting anticoagulant until there is a stable therapeutic INR. In this study, results from bridging with subcutaneous low molecular weight heparin (LMWH) or oral Rivaroxaban were compared.MethodsOne hundred and twenty-four patients received LMWH and 98 patients received Rivaroxaban, both in addition to Warfarin. Patients were assessed at 1 and 4 weeks after treatment initiation for thrombus progression, bleeding, clinic attendance and INR.FindingsThe treatment groups were well matched. There were no significant differences between the treatment groups for any of the end-points at either 1 week or 4 weeks.ImplicationsIn ambulant patients with DVT treated with Warfarin both Rivaroxaban and LMWH are suitable for use in the early phase of Warfarin treatment until therapeutic INR is achieved. Rivaroxaban is a suitable alternative to LMWH for patients who prefer not to have injections.© 2021 John Wiley & Sons Ltd.

16 keywords...

hide…